AU2001238034A1 - Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) - Google Patents

Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Info

Publication number
AU2001238034A1
AU2001238034A1 AU2001238034A AU3803401A AU2001238034A1 AU 2001238034 A1 AU2001238034 A1 AU 2001238034A1 AU 2001238034 A AU2001238034 A AU 2001238034A AU 3803401 A AU3803401 A AU 3803401A AU 2001238034 A1 AU2001238034 A1 AU 2001238034A1
Authority
AU
Australia
Prior art keywords
disease
apc
diseases
vascular
activated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238034A
Inventor
John H Griffin
Berislav Y. Zlokovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
University of Southern California USC
Original Assignee
Scripps Research Institute
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, University of Southern California USC filed Critical Scripps Research Institute
Publication of AU2001238034A1 publication Critical patent/AU2001238034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Abstract

The present invention provides methods for treating subjects having or at risk of having a neuropathological disorder or brain inflammatory diseases with and without vascular involvement, and systemic inflammatory vascular disease by administering a therapeutically effective amount of Activated Protein C (APC) to the subject. Brain disorders and brain inflammatory vascular diseases that can be treated by the invention method include all neurodegenerative diseases with different types of neuronal dysfunction, including stroke, Alzheimer's disease, Parkinson's disease, Huntington disease, neuroimmunological disorders such as multiple scelrosis and Gullian-Barre, encephalitis, meningitis, as well as other peripheral vascular diseases, such as diabetes, hypertension, artheriosclerosis. Also included are methods of treatment using APC in combination with a co-factor, such as Protein S.
AU2001238034A 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) Abandoned AU2001238034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18022700P 2000-02-04 2000-02-04
US60/180,227 2000-02-04
PCT/US2001/003758 WO2001056532A2 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Publications (1)

Publication Number Publication Date
AU2001238034A1 true AU2001238034A1 (en) 2001-08-14

Family

ID=22659693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238034A Abandoned AU2001238034A1 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Country Status (8)

Country Link
US (1) US7074402B2 (en)
EP (1) EP1255556B1 (en)
JP (1) JP2004508280A (en)
AT (1) ATE504310T1 (en)
AU (1) AU2001238034A1 (en)
CA (1) CA2398929C (en)
DE (1) DE60144366D1 (en)
WO (1) WO2001056532A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
EP1404412B1 (en) 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1572134B1 (en) * 2002-09-30 2011-09-28 Zz Biotech L.L.C. Protein s for use as a neuroprotective agent
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
EP1567199B1 (en) * 2002-12-05 2014-07-23 Zz Biotech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co Treatment for autoimmune and inflammatory conditions
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
NZ582930A (en) 2007-07-20 2012-11-30 Diamedica Inc Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions
JP2012524725A (en) * 2009-04-22 2012-10-18 サノミューン・インコーポレイテッド Tissue kallikrein for treating Huntington's disease
KR102068010B1 (en) 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 Treatment of inflammatory skin disorders
CN104122396A (en) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 Application of vitamin K-dependent protein S as diabetes marker
ES2890675T3 (en) 2014-04-16 2022-01-21 Zz Biotech Llc APC for use in the treatment of abnormal skin scars
CN105806818B (en) * 2016-04-01 2019-11-22 南京医科大学 Detect the active method and its application of blood platelet nmda receptor
WO2017212476A1 (en) 2016-06-05 2017-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Novel molecules for the treatment of inflammation
CA3054962A1 (en) 2017-03-09 2018-09-13 Rick PAULS Dosage forms of tissue kallikrein 1
EP4122481A4 (en) * 2020-03-24 2023-04-05 Talengen International Limited Method and medicine for treating huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
AT402153B (en) * 1989-06-26 1997-02-25 Immuno Ag PROTEIN-S CONTAINING PHARMACEUTICAL PREPARATION
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
TR199902335T2 (en) 1997-03-24 2000-01-21 Eli Lilly And Company Treatment of vascular disorders.
EA199901112A1 (en) * 1997-06-05 2000-06-26 Эли Лилли Энд Компани METHODS OF TREATMENT OF THROMBOTIC DISORDERS
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP1255556A4 (en) 2003-07-02
WO2001056532A2 (en) 2001-08-09
ATE504310T1 (en) 2011-04-15
EP1255556A2 (en) 2002-11-13
CA2398929C (en) 2011-05-31
DE60144366D1 (en) 2011-05-19
CA2398929A1 (en) 2001-08-09
US20020028199A1 (en) 2002-03-07
JP2004508280A (en) 2004-03-18
US7074402B2 (en) 2006-07-11
EP1255556B1 (en) 2011-04-06
WO2001056532A9 (en) 2003-01-09
WO2001056532A3 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU2001238034A1 (en) Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
WO2004110389A3 (en) Sigma ligands for neuronal regeneration and functional recovery
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
TW264480B (en)
CY1111359T1 (en) Memantine for the treatment of mild to moderate ALZHEIMER
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2000072880A3 (en) Prevention and treatment of amyloidogenic disease
PT2527315E (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
WO2007053580A3 (en) Sigma ligands for neuronal regeneration and functional recovery
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2004028468A3 (en) Methods and compositions for treatment of neurological disorder
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
EP1365771A4 (en) Method of treating certain eye diseases